Business
Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy
Collaboration will combine Lexeo expertise in cardiac genetic medicine with Johnson & Johnson’s expertise in cardiovascular therapeutics and circulatory technologies, including Impella™ heart pumps Agreement will enable accelerated development of a preclinical cardiac target using novel, localized routes of viral gene therapy administration NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel
About this update from Lexeo Therapeutics, Inc.
[{"type":"image","alt":"Lexeo Therapeutics","displaySize":"","headline":null,"caption":"Lexeo Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":116,"url":"https://media.zenfs.com/en/globenewswire.com/12a596ea7105503183002156834260ac"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZNNLd9kZ10lMRyd7r.aoKQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/12a596ea7105503183002156834260ac","width":300,"height":116}},"lazy":false},{"type":"text","content":"Collaboration will combine Lexeo expertise in cardiac genetic medicine with Johnson & Johnson’s expertise in cardiovascular therapeutics and circulatory technologies, including Impella™ heart pumps ","length":201,"tagName":"p"},{"type":"text","content":"Agreement will enable accelerated development of a preclinical cardiac target using novel, localized routes of viral gene therapy administration","length":144,"tagName":"p"},{"type":"text","content":"NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced a research collaboration with Johnson & Johnson, a global leader in cardiovascular health, to investigate localized cardiac delivery of gene therapy. The collaboration seeks to advance the potential efficacy and safety profile of gene therapy for genetically mediated cardiovascular diseases by concentrating AAV (adeno associated viral) delivery to the heart by investigating cutting-edge routes of administration using Impella™ heart pump technology. Impella heart pumps provide direct cardiac unloading to enhance myocardial perfusion, which may help delivery of gene therapy.","length":796,"tagName":"p"},{"type":"text","content":"“This collaboration represents an exciting step toward unlocking the full potential of cardiac gene therapy,” said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics. “By concentrating delivery to the heart with localized routes of administration leveraging Impella heart pumps, we aim to substantially reduce required AAV doses and improve gene therapy safety while maximizing transgene expression and clinical efficacy. We are thrilled to pair Lexeo’s leadership in cardiac genetic medicine with Impella’s world...